Drug intelligence / Profile preview

WXWH0226

Development stage: Unknown
Lead developer: Guizhou Inoqini Technology
Modality: Small Molecules
Administration: Oral

Overview

WXWH0226 is a small molecule inhibitor of monoamine oxidase B (MAO-B) being developed by Guizhou Inochini Technology for the treatment of Parkinson's disease. MAO-B is an enzyme responsible for the oxidative deamination of dopamine in the central nervous system; by selectively inhibiting this enzyme, WXWH0226 aims to increase the availability of dopamine in the synaptic cleft, thereby alleviating the motor symptoms associated with Parkinson's disease. The drug is currently undergoing clinical evaluation in China, with studies assessing its safety, tolerability, pharmacokinetics, and preliminary efficacy in both healthy volunteers and patients with Parkinson's disease.

Targets

LRRK2 (Leucine-rich repeat serine/threonine-protein kinase 2)

Beyond the preview

Go deeper on WXWH0226.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WXWH0226.

Explore the full profile